Additional file 3: of Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Figure S2. Sensitivity analysis of ORR (A) and DCR (B) (TIF 1268 kb)